AU2021260964A1 - Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof - Google Patents

Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof Download PDF

Info

Publication number
AU2021260964A1
AU2021260964A1 AU2021260964A AU2021260964A AU2021260964A1 AU 2021260964 A1 AU2021260964 A1 AU 2021260964A1 AU 2021260964 A AU2021260964 A AU 2021260964A AU 2021260964 A AU2021260964 A AU 2021260964A AU 2021260964 A1 AU2021260964 A1 AU 2021260964A1
Authority
AU
Australia
Prior art keywords
effective amount
administering
days
agent
time period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021260964A
Other languages
English (en)
Inventor
Rebecca BOOHAKER
Hyunyong Cho
Doo Young Jung
Jin Soo Lee
Mark J. Suto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pinotbio Inc
Southern Research Institute
Original Assignee
Pinotbio Inc
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinotbio Inc, Southern Research Institute filed Critical Pinotbio Inc
Publication of AU2021260964A1 publication Critical patent/AU2021260964A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021260964A 2020-04-23 2021-04-22 Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof Pending AU2021260964A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014346P 2020-04-23 2020-04-23
US63/014,346 2020-04-23
PCT/US2021/028726 WO2021216936A1 (en) 2020-04-23 2021-04-22 Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Publications (1)

Publication Number Publication Date
AU2021260964A1 true AU2021260964A1 (en) 2022-12-01

Family

ID=78221459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021260964A Pending AU2021260964A1 (en) 2020-04-23 2021-04-22 Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Country Status (8)

Country Link
US (2) US12208112B2 (https=)
EP (1) EP4138843A4 (https=)
JP (1) JP2023524912A (https=)
KR (1) KR20230004768A (https=)
CN (1) CN115768432A (https=)
AU (1) AU2021260964A1 (https=)
CA (1) CA3176543A1 (https=)
WO (1) WO2021216936A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
KR20240108406A (ko) 2021-10-19 2024-07-09 아키라바이오, 인크. 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도
WO2024191252A1 (ko) * 2023-03-14 2024-09-19 주식회사 피노바이오 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형
CN117187391B (zh) * 2023-09-15 2025-03-18 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用
WO2025100762A1 (ko) * 2023-11-08 2025-05-15 한국생명공학연구원 4'-티오-5-아자-2'-디옥시사이티딘을 포함하는 간질환의 개선, 예방 또는 치료용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
ES2402799T3 (es) 1998-07-23 2013-05-09 Southern Research Institute Prepreparación de compuestos de tioarabinofuranosilo y utilización de los mismos
WO2004018494A1 (ja) 2002-08-22 2004-03-04 Geneticlab Co., Ltd. ４’−チオヌクレオチド
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
KR101125932B1 (ko) 2006-12-06 2012-03-22 아이디유엔 파마슈티칼즈, 인코포레이티드 (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
EP3782612B1 (en) 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2011109383A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy -4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
WO2011109012A1 (en) * 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
BR112016028641A2 (pt) * 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
US10662214B2 (en) 2015-04-03 2020-05-26 Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd. Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
HK1252245A1 (zh) 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc 用於治疗癌症的核苷酸
EP3207932A1 (en) * 2016-02-19 2017-08-23 Universität Stuttgart Dna methyltransferase inhibitors for rett syndrome therapy
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
JP7520822B2 (ja) 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用

Also Published As

Publication number Publication date
WO2021216936A1 (en) 2021-10-28
US20250082662A1 (en) 2025-03-13
KR20230004768A (ko) 2023-01-06
US12208112B2 (en) 2025-01-28
JP2023524912A (ja) 2023-06-13
EP4138843A1 (en) 2023-03-01
US20210330689A1 (en) 2021-10-28
CN115768432A (zh) 2023-03-07
EP4138843A4 (en) 2024-07-10
CA3176543A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US20250082662A1 (en) Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof
DE69233115T2 (de) Weitere therapeutische Verwendungen von L-Methionine und Zusammensetzungen
WO2005016358A1 (en) Anthelmintic formulations
JPWO2014038630A1 (ja) セシウム排泄剤、有害金属排泄剤、飲食品、飼料および医薬品
US20140274937A1 (en) Methods of treating hematologic cancers
BG107038A (bg) Гелен паразитициден състав
JP2019516793A (ja) イミダクロプリド、モキシデクチン及びプラジカンテルを含む、イヌを冒す外部及び内部の寄生虫病の治療及び予防用の皮膚局所適用（スポットオン）するための獣医学的組成物
CN114206330A (zh) 软骨再生促进用组合物
US7582612B2 (en) Multi-action anthelmintic formulations
Sherman et al. Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation
Krotova et al. The effectiveness of the use of multivitamin preparations in feeding with hypovitaminosis of piglets
Semenenko et al. Possibilities of using natural aluminosilicates in the development of medicines at hepatosis in poultry
Al-Ankari et al. Effect of antibacterial growth promoters on the immune system of broiler chicks
Ridley et al. The efficacy of pyrantel pamoate against ascarids and hookworms in cats
TWI731241B (zh) 增重化合物之組合物及其長期使用方法
DE69529575T2 (de) Arzneimittel zur behandlung von parasitischen und pilzartigen infektionen
Smith et al. Sheep breed differences in pentobarbitone sleeping-time and response to experimental sporidesmin intoxication
WO2005016356A1 (en) Improved anthelmintic formulations
CN106554385B (zh) 多肽类化合物及其在畜禽方面的应用
Kano et al. Systemic treatment of sterile panniculitis with tacolimus and prednisolone in dogs
CN1379676A (zh) 血浆代用品组合物
CN100391487C (zh) 一种治疗白细胞减少症的制剂及其制法
DE60215051T2 (de) Zusammensetzung und verfahren zur behandlung chronischer allograft-abstossung
CN106821975A (zh) 一种莫奈太尔口服液及其制备方法和应用
Gear Practical update on canine lymphoma: 2. Treatment